 GAITHERSBURG, Md., Sept. 09, 2022 GLOBE NEWSWIRE -- NexImmune, Inc. Nasdaq: NEXI, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET. 